Blinded, controlled field trial of two commercially available mycoplasma bovis bacterin vaccines in veal calves

Marty K. Soehnlen, Adnan Aydin, Eugene Lengerich, Beth A. Houser, Ginger D. Fenton, Hannah R. Lysczek, Carolyn M. Burns, Louise I. Byler, Arthur L. Hattel, David R. Wolfgang, Bhushan M. Jayarao

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Mycoplasma bovis is an etiologic agent of pneumonia, arthritis, and otitis in young calves, such as those found in the special-fed veal industry. We conducted a blinded, controlled trial of two commercially available M. bovis bacterin vaccines for the prevention of respiratory disease in calves associated with M. bovis infection. Calves were randomly assigned to a subcutaneous treatment of vaccine A (n= 50), adjuvant A (n= 50), vaccine B (n= 50), or 0.9% sterile saline solution (n= 50) beginning at 27 days of age. Upper-respiratory tract colonization was not impacted by vaccination status. Vaccine A significantly reduced the presence of lung lesions (p= 0.0325), however there was no significant reduction of M. bovis in lung lesions. Vaccine B did not significantly reduce total lung lesions or M. bovis-specific lung lesions. The relative risk was determined to be 0.56, 1.0, and 1.36 for vaccine A, adjuvant A, and vaccine B, respectively. There was no association between the total specific antibody isotype (IgM, IgG1, IgG2, IgA) concentrations or M. bovis antibodies and the M. bovis-associated morbidity in the veal calves. Under the field conditions of this study, observed vaccine efficacy for vaccine A and vaccine B was 44% and less than 1%, respectively.

Original languageEnglish (US)
Pages (from-to)5347-5354
Number of pages8
JournalVaccine
Volume29
Issue number33
DOIs
StatePublished - Jul 26 2011

Fingerprint

Mycoplasma bovis
Bacterial Vaccines
veal calves
field experimentation
Vaccines
vaccines
lesions (animal)
lungs
Lung
calves
adjuvants
Immunoglobulin G
Mycoplasma Infections
veal
Otitis
antibodies
Antibodies
arthritis
relative risk
respiratory system

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Soehnlen, Marty K. ; Aydin, Adnan ; Lengerich, Eugene ; Houser, Beth A. ; Fenton, Ginger D. ; Lysczek, Hannah R. ; Burns, Carolyn M. ; Byler, Louise I. ; Hattel, Arthur L. ; Wolfgang, David R. ; Jayarao, Bhushan M. / Blinded, controlled field trial of two commercially available mycoplasma bovis bacterin vaccines in veal calves. In: Vaccine. 2011 ; Vol. 29, No. 33. pp. 5347-5354.
@article{038cae73001a4c56b41f8bc879235ab7,
title = "Blinded, controlled field trial of two commercially available mycoplasma bovis bacterin vaccines in veal calves",
abstract = "Mycoplasma bovis is an etiologic agent of pneumonia, arthritis, and otitis in young calves, such as those found in the special-fed veal industry. We conducted a blinded, controlled trial of two commercially available M. bovis bacterin vaccines for the prevention of respiratory disease in calves associated with M. bovis infection. Calves were randomly assigned to a subcutaneous treatment of vaccine A (n= 50), adjuvant A (n= 50), vaccine B (n= 50), or 0.9{\%} sterile saline solution (n= 50) beginning at 27 days of age. Upper-respiratory tract colonization was not impacted by vaccination status. Vaccine A significantly reduced the presence of lung lesions (p= 0.0325), however there was no significant reduction of M. bovis in lung lesions. Vaccine B did not significantly reduce total lung lesions or M. bovis-specific lung lesions. The relative risk was determined to be 0.56, 1.0, and 1.36 for vaccine A, adjuvant A, and vaccine B, respectively. There was no association between the total specific antibody isotype (IgM, IgG1, IgG2, IgA) concentrations or M. bovis antibodies and the M. bovis-associated morbidity in the veal calves. Under the field conditions of this study, observed vaccine efficacy for vaccine A and vaccine B was 44{\%} and less than 1{\%}, respectively.",
author = "Soehnlen, {Marty K.} and Adnan Aydin and Eugene Lengerich and Houser, {Beth A.} and Fenton, {Ginger D.} and Lysczek, {Hannah R.} and Burns, {Carolyn M.} and Byler, {Louise I.} and Hattel, {Arthur L.} and Wolfgang, {David R.} and Jayarao, {Bhushan M.}",
year = "2011",
month = "7",
day = "26",
doi = "10.1016/j.vaccine.2011.05.092",
language = "English (US)",
volume = "29",
pages = "5347--5354",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "33",

}

Soehnlen, MK, Aydin, A, Lengerich, E, Houser, BA, Fenton, GD, Lysczek, HR, Burns, CM, Byler, LI, Hattel, AL, Wolfgang, DR & Jayarao, BM 2011, 'Blinded, controlled field trial of two commercially available mycoplasma bovis bacterin vaccines in veal calves', Vaccine, vol. 29, no. 33, pp. 5347-5354. https://doi.org/10.1016/j.vaccine.2011.05.092

Blinded, controlled field trial of two commercially available mycoplasma bovis bacterin vaccines in veal calves. / Soehnlen, Marty K.; Aydin, Adnan; Lengerich, Eugene; Houser, Beth A.; Fenton, Ginger D.; Lysczek, Hannah R.; Burns, Carolyn M.; Byler, Louise I.; Hattel, Arthur L.; Wolfgang, David R.; Jayarao, Bhushan M.

In: Vaccine, Vol. 29, No. 33, 26.07.2011, p. 5347-5354.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Blinded, controlled field trial of two commercially available mycoplasma bovis bacterin vaccines in veal calves

AU - Soehnlen, Marty K.

AU - Aydin, Adnan

AU - Lengerich, Eugene

AU - Houser, Beth A.

AU - Fenton, Ginger D.

AU - Lysczek, Hannah R.

AU - Burns, Carolyn M.

AU - Byler, Louise I.

AU - Hattel, Arthur L.

AU - Wolfgang, David R.

AU - Jayarao, Bhushan M.

PY - 2011/7/26

Y1 - 2011/7/26

N2 - Mycoplasma bovis is an etiologic agent of pneumonia, arthritis, and otitis in young calves, such as those found in the special-fed veal industry. We conducted a blinded, controlled trial of two commercially available M. bovis bacterin vaccines for the prevention of respiratory disease in calves associated with M. bovis infection. Calves were randomly assigned to a subcutaneous treatment of vaccine A (n= 50), adjuvant A (n= 50), vaccine B (n= 50), or 0.9% sterile saline solution (n= 50) beginning at 27 days of age. Upper-respiratory tract colonization was not impacted by vaccination status. Vaccine A significantly reduced the presence of lung lesions (p= 0.0325), however there was no significant reduction of M. bovis in lung lesions. Vaccine B did not significantly reduce total lung lesions or M. bovis-specific lung lesions. The relative risk was determined to be 0.56, 1.0, and 1.36 for vaccine A, adjuvant A, and vaccine B, respectively. There was no association between the total specific antibody isotype (IgM, IgG1, IgG2, IgA) concentrations or M. bovis antibodies and the M. bovis-associated morbidity in the veal calves. Under the field conditions of this study, observed vaccine efficacy for vaccine A and vaccine B was 44% and less than 1%, respectively.

AB - Mycoplasma bovis is an etiologic agent of pneumonia, arthritis, and otitis in young calves, such as those found in the special-fed veal industry. We conducted a blinded, controlled trial of two commercially available M. bovis bacterin vaccines for the prevention of respiratory disease in calves associated with M. bovis infection. Calves were randomly assigned to a subcutaneous treatment of vaccine A (n= 50), adjuvant A (n= 50), vaccine B (n= 50), or 0.9% sterile saline solution (n= 50) beginning at 27 days of age. Upper-respiratory tract colonization was not impacted by vaccination status. Vaccine A significantly reduced the presence of lung lesions (p= 0.0325), however there was no significant reduction of M. bovis in lung lesions. Vaccine B did not significantly reduce total lung lesions or M. bovis-specific lung lesions. The relative risk was determined to be 0.56, 1.0, and 1.36 for vaccine A, adjuvant A, and vaccine B, respectively. There was no association between the total specific antibody isotype (IgM, IgG1, IgG2, IgA) concentrations or M. bovis antibodies and the M. bovis-associated morbidity in the veal calves. Under the field conditions of this study, observed vaccine efficacy for vaccine A and vaccine B was 44% and less than 1%, respectively.

UR - http://www.scopus.com/inward/record.url?scp=79960361641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960361641&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.05.092

DO - 10.1016/j.vaccine.2011.05.092

M3 - Article

C2 - 21664397

AN - SCOPUS:79960361641

VL - 29

SP - 5347

EP - 5354

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 33

ER -